LL-37 for Autoimmune Conditions
Research, mechanism, dosing, and effectiveness of LL-37 for autoimmune conditions.
Quick Answer
LL-37 may help modulate immune responses in autoimmune conditions.
Evidence Level
Human Trials
Typical Dose
100-200 mcg daily
Results Timeline
Immune modulation over 4-8 weeks
FDA Status
Research Only
How LL-37 Works for Autoimmune Conditions
Balances immune system activity.
About Autoimmune Conditions
Modulation of overactive immune responses in autoimmune conditions.
Research Evidence
Research demonstrates broad antimicrobial activity including against antibiotic-resistant bacteria. Studies show wound healing benefits, anti-biofilm effects, and immune modulation. Being investigated for chronic infections and wound healing applications.
Dosing for Autoimmune Conditions
Recommended Dose
100-200 mcg daily
Frequency
Once daily
Administration
Subcutaneous injection or topical
Duration
Variable by protocol
Note: Antimicrobial peptide. Used for infections, biofilm disruption. Some use higher doses for acute infections.
What to Expect
Initial adjustment period. Some users may notice subtle changes.
Early benefits often become noticeable. Continue consistent use.
Most users report meaningful improvements by this point.
Full effects typically realized. Reassess and adjust as needed.
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Injection site reactions (common)
- •Skin toxicity (ulcers, burning)
- •Allergic reactions
- •May trigger histamine release - use caution with MCAS or histamine sensitivity
- •May contribute to autoimmune conditions
- •High-dose toxicity concerns
Frequently Asked Questions
Does LL-37 help with autoimmune conditions?
LL-37 may help modulate immune responses in autoimmune conditions.
How does LL-37 work for autoimmune conditions?
Balances immune system activity....
What dose of LL-37 should I use for autoimmune conditions?
100-200 mcg daily
How long until I see results?
Immune modulation over 4-8 weeks
Other Peptides for Autoimmune Conditions
These peptides are also researched for autoimmune conditions.
Thymosin Alpha-1
Clinical TrialsA naturally occurring thymic peptide that enhances immune function. Approved in over 35 countries for hepatitis B/C and as an immune adjuvant.
KPV
PreclinicalA tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH). Known for potent anti-inflammatory effects, particularly in the gut.
VIP
Clinical TrialsA naturally occurring peptide with immunomodulatory and anti-inflammatory effects. Being studied for ARDS, pulmonary hypertension, and autoimmune conditions.
Thymogen
Clinical TrialsA synthetic dipeptide (Glu-Trp) bioregulator derived from Thymalin, a thymus extract. One of Professor Khavinson's key immunomodulatory peptides, shown to stimulate T-lymphocyte development and normalize immune function. Has been used clinically in Russia for immune support.
Educational Information Only
This information about LL-37 for autoimmune conditions is for educational purposes only. Always consult with qualified healthcare providers before using any peptide. Individual results may vary.